PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS
The complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment. The aim of our work was to study the pharmacogenetics features of pharmacotherapy of patients with non-alcoholic fatty liv...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
SINAPS LLC
2018-02-01
|
| Series: | Архивъ внутренней медицины |
| Subjects: | |
| Online Access: | https://www.medarhive.ru/jour/article/view/746 |
| _version_ | 1797883765074165760 |
|---|---|
| author | A. L. Khokhlov A. N. Yavorsky N. O. Pozdnyakov J. V. Rybachkova E. S. Emelianov A. A. Khokhlov A. E. Miroshnikov S. O. Pozdnyakov |
| author_facet | A. L. Khokhlov A. N. Yavorsky N. O. Pozdnyakov J. V. Rybachkova E. S. Emelianov A. A. Khokhlov A. E. Miroshnikov S. O. Pozdnyakov |
| author_sort | A. L. Khokhlov |
| collection | DOAJ |
| description | The complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment. The aim of our work was to study the pharmacogenetics features of pharmacotherapy of patients with non-alcoholic fatty liver disease, with various forms of IHD, and patients taking statins. We investigated 4 study groups: I — 60 patients with 2 type of diabetes and non-alcoholic fatty liver disease (APOE polymorphism); II — 187 patients with IHD (eNOS, AGTR2, CYP2D6 polymorphisms); III — 111 people with AH and CHF (polymorphisms: AGT: 704 (Met235Thr), AGT:521 (Thr174Met), AGTR1: 1166, AGTR2: 1675, CYP11B2: -344, GNB3: 825, ADD1: 1378 (Gly460Trp), NOS3: -786); IV — 62 patients taking atorvastatin (SLCO1B1*5 polymorphism). Patients with E2, E4 alleles of the APOE gene, taking essential phospholipids, improved parameters of total cholesterol, HDL, LDL, CA, AP; patients with E3 alleles had a positive dynamics of cholesterol, HDL, TG, LDL, VLDL, CA, urea. Patients having “slow” allelic variants of the gene CYP2D6*10, CYP2D6*4 had received metoprolol, had greater decrease in heart rate: 1.6 times for CYP2D6*10, 1.7 — for CYP2D6*4. Earlier debut of IHD is noted in patients with TT variants of the eNOS gene comparing the patients with GG and GT variants. Dosages of perindopril depend on AGTR2 gene polymorphisms. The prevalence of polymorphisms AGTR2: 1675, CYP11B2: -344, NOS3: -786, AGT: 704, GNB3: 825 increases with the increase in the stage of CHF. The parameters of intracardiac hemodynamics in patients with CHF are associated with AGT: 704, NOS3:-786, GNB3: 825, ADD1: 1378, AGT: 521 polymorphisms. Allele C of the SLCO1B1*5 gene is associated with an additional risk of statin-induced myopathy. So the treatment of diseases associated with atherosclerosis, needs using of a personalized approach for more effective and safe therapy. |
| first_indexed | 2024-04-10T03:57:00Z |
| format | Article |
| id | doaj.art-31bf942db4b14a65a049a70b29d53deb |
| institution | Directory Open Access Journal |
| issn | 2226-6704 2411-6564 |
| language | Russian |
| last_indexed | 2024-04-10T03:57:00Z |
| publishDate | 2018-02-01 |
| publisher | SINAPS LLC |
| record_format | Article |
| series | Архивъ внутренней медицины |
| spelling | doaj.art-31bf942db4b14a65a049a70b29d53deb2023-03-13T07:12:08ZrusSINAPS LLCАрхивъ внутренней медицины2226-67042411-65642018-02-0181455210.20514/2226-6704-2018-8-1-45-52655PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSISA. L. Khokhlov0A. N. Yavorsky1N. O. Pozdnyakov2J. V. Rybachkova3E. S. Emelianov4A. A. Khokhlov5A. E. Miroshnikov6S. O. Pozdnyakov7ФГБОУ ВО «Ярославский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииПущинский естественнонаучного института Минобрнауки РоссииФГБОУ ВО «Ярославский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииФГБОУ ВО «Ярославский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииГУЗ ЯО «Клиническая больница № 8»ФГБОУ ВО «Ярославский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииФГБОУ ВО «Ярославский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииФГБОУ ВО «Ярославский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииThe complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment. The aim of our work was to study the pharmacogenetics features of pharmacotherapy of patients with non-alcoholic fatty liver disease, with various forms of IHD, and patients taking statins. We investigated 4 study groups: I — 60 patients with 2 type of diabetes and non-alcoholic fatty liver disease (APOE polymorphism); II — 187 patients with IHD (eNOS, AGTR2, CYP2D6 polymorphisms); III — 111 people with AH and CHF (polymorphisms: AGT: 704 (Met235Thr), AGT:521 (Thr174Met), AGTR1: 1166, AGTR2: 1675, CYP11B2: -344, GNB3: 825, ADD1: 1378 (Gly460Trp), NOS3: -786); IV — 62 patients taking atorvastatin (SLCO1B1*5 polymorphism). Patients with E2, E4 alleles of the APOE gene, taking essential phospholipids, improved parameters of total cholesterol, HDL, LDL, CA, AP; patients with E3 alleles had a positive dynamics of cholesterol, HDL, TG, LDL, VLDL, CA, urea. Patients having “slow” allelic variants of the gene CYP2D6*10, CYP2D6*4 had received metoprolol, had greater decrease in heart rate: 1.6 times for CYP2D6*10, 1.7 — for CYP2D6*4. Earlier debut of IHD is noted in patients with TT variants of the eNOS gene comparing the patients with GG and GT variants. Dosages of perindopril depend on AGTR2 gene polymorphisms. The prevalence of polymorphisms AGTR2: 1675, CYP11B2: -344, NOS3: -786, AGT: 704, GNB3: 825 increases with the increase in the stage of CHF. The parameters of intracardiac hemodynamics in patients with CHF are associated with AGT: 704, NOS3:-786, GNB3: 825, ADD1: 1378, AGT: 521 polymorphisms. Allele C of the SLCO1B1*5 gene is associated with an additional risk of statin-induced myopathy. So the treatment of diseases associated with atherosclerosis, needs using of a personalized approach for more effective and safe therapy.https://www.medarhive.ru/jour/article/view/746фармакогенетикаибсхснполиморфизмapoeenosagtr2cyp2d6agt:704 (met235thr)agt:521 (thr174met)agtr1:1166agtr2:1675cyp11b2: -344gnb3: 825add1:1378 (gly460trp)nos3: -786slco1b*5метопрололаторвастатин |
| spellingShingle | A. L. Khokhlov A. N. Yavorsky N. O. Pozdnyakov J. V. Rybachkova E. S. Emelianov A. A. Khokhlov A. E. Miroshnikov S. O. Pozdnyakov PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS Архивъ внутренней медицины фармакогенетика ибс хсн полиморфизм apoe enos agtr2 cyp2d6 agt:704 (met235thr) agt:521 (thr174met) agtr1:1166 agtr2:1675 cyp11b2: -344 gnb3: 825 add1:1378 (gly460trp) nos3: -786 slco1b*5 метопролол аторвастатин |
| title | PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS |
| title_full | PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS |
| title_fullStr | PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS |
| title_full_unstemmed | PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS |
| title_short | PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS |
| title_sort | pharmacogenetic features of therapy of patients with atherosclerosis |
| topic | фармакогенетика ибс хсн полиморфизм apoe enos agtr2 cyp2d6 agt:704 (met235thr) agt:521 (thr174met) agtr1:1166 agtr2:1675 cyp11b2: -344 gnb3: 825 add1:1378 (gly460trp) nos3: -786 slco1b*5 метопролол аторвастатин |
| url | https://www.medarhive.ru/jour/article/view/746 |
| work_keys_str_mv | AT alkhokhlov pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis AT anyavorsky pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis AT nopozdnyakov pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis AT jvrybachkova pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis AT esemelianov pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis AT aakhokhlov pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis AT aemiroshnikov pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis AT sopozdnyakov pharmacogeneticfeaturesoftherapyofpatientswithatherosclerosis |